Michelle Xia, PhDChairman and CEO at Akeso Biopharma Inc.
Dr. Michelle Xia has over 20 years of experience in biopharmaceutical industry and academic research. Prior to founding Akeso Biopharma, she was Senior Vice President at Crown Bioscience, in charge of the Biologics Business Unit and Pfizer-Crown Asian Cancer Research Center. Prior to joining Crown Bioscience, Dr. Xia worked at PDL BioPharma (acquired by Abbott Labs) in the San Francisco Bay Area, one of the pioneer therapeutic antibody technology and drug development company, where she served as a core member in CMC project teams overseeing drug substance and product process development/manufacturing, technology transfer and FDA registration/IND enabling process. Prior to that, Dr. Xia worked at the CMC Process Development Department of Bayer in Berkeley. Her responsibilities there included building the Pathogen Safety facility at Bayer and managing viral safety evaluation/purification process validation for manufacturing biological products. Dr. Xia began her biopharmaceutical career at AXY Pharmaceuticals, which was acquired by Celera Genomics in 2001. During the six-year service with AXY/Celera, she played both scientific and managerial roles in drug discovery programs from target validation through IND enabling.
Dr. Xia received her B. S. in Biochemistry from Zhongshan University in China and earned her Ph. D. in Molecular Biology and Microbiology from University of Newcastle in U.K. She did her postdoctoral research at University of Glasgow in U.K. and cancer immune therapy research at University of Louisville Medical School in the U.S.